The Antimicrobial Susceptibility Testing Market Size was valued at USD 3.57 billion in 2023 and is expected to reach USD 5.35 billion by 2031, and grow at a CAGR of 5.2% over the forecast period 2024-2031.
The uptake of antimicrobial susceptibility testing for the treatment of infections is expected to be increased due to increasing market penetration of personalised medicinal products, as well as an overuse and abuse of antibiotics that may lead to antibacterial resistance. In addition, market growth is projected to be driven by the growing use of antimicrobial susceptibility testing by biotechnology, pharmaceuticals and biopharma companies for developing novel & efficient medicinal products. New opportunities are also opening up for the market with the availability of modern products. For example, NanoSynex Ltd. made an announcement of its plan to market the novel rapid AST in January 2023.
To get more information on Antimicrobial Susceptibility Testing Market - Request Sample Report
DRIVERS
The government's efforts to identify and control antimicrobial resistant organisms are increasing.
Increasing market support, R&D grants and Public Private Partnerships
The rise of multidrug resistance as a result of substance abuse.
With the rise of medication resistance globally, diseases are becoming increasingly challenging to treat, leading to a decline in the effectiveness of antibiotics and, ultimately, contributing to higher mortality rates. For example, new antibiotics are urgently needed to treat carbapenem resistant gram-negative bacterial infections, according to the WHO list of priority pathogens.
RESTRAINTS
Automated ID/AST systems are extremely expensive
The cost of automated laboratory equipment is high.
There are top of the line features and functions in automated antimicrobial laboratory equipment, and it costs a lot of money. Automated AST systems reduce incubation and detection time. Another obstacle to this industry is the cost of maintaining these devices, which are well suited for cutting edge software and require periodic maintenance.
OPPORTUNITIES
Initiatives to raise awareness about antimicrobial resistance and its management
Growth in the emerging markets
There are significant opportunities for players in the antimicrobial susceptibility testing market in emerging countries such as Asia Pacific, India, China and Japan. Also, the rising demand for antimicrobial susceptibility testing in these nations is driven by the rapid expansion of medical tourism, the growth of the adult population (aged 20 and above), and the escalating prevalence of drug abuse. The countries also have a strong and skilled workforce, which has great knowledge of the latest technological developments. In addition, these countries have favourable import and export policies and are underpenetrated in most respects, which could help companies to develop their brands. The regions are helping to develop and update their technologies by increasing the number of skilled technicians and by becoming more aware of new technologies.
CHALLENGES
Complex regulatory procedures are slowing down the approval of antimicrobial tests.
One of the biggest problems with antibiotic susceptibility testing is that there are too many gaps in time between determining breakpoints, approving new antibiotics and making them available on the market. The FDA sets certain threshold values when pharmaceutical companies submit applications for new medications which are not approved. The lack of clinically defined thresholds for some medicinal products is also limiting the adoption of antimicrobial susceptibility agents. For example, as an illustration, clinical cutoffs for assessing the effectiveness of antifungal treatment in invasive non-Aspergillus mold infections are currently unavailable.
The ongoing conflict between Russia and Ukraine reverberates through the realm of antimicrobial susceptibility testing (AST), amplifying challenges across various fronts. Supply chains, essential to the timely delivery of laboratory essentials, are experiencing disruptions resulting in shortages and delays on key tests which directly impact patient care. Furthermore, the conflict-induced damage to laboratory infrastructure and sporadic interruptions in power supply compound the problem, impeding the accurate execution of AST and complicating treatment decisions for healthcare providers. Displacement of skilled healthcare workers is an additional complication in the current shortage, affecting laboratory capacity and adversely affecting AST's effectiveness. In addition, the global collaboration and sharing of data could be impeded by geopolitical tensions that would prevent efforts to detect antibiotic resistance trends and develop efficient strategies. These complex challenges underline the need to develop a coordinated approach to addressing AST in conflict zones, as well as protecting public health against antimicrobial resistance around the world, calling for an immediate effort.
A reduction in the number of patients and, consequently, a reduction in the demand for AST can result from reduced demand for healthcare services, in particular non urgent treatments. This decrease in demand can further strain laboratory resources, and could lead to an underutilisation of AST capacity. In addition, the challenges faced by healthcare facilities in maintaining and upgrading AST infrastructure are exacerbated by limited access to finance due to economic slowdown.
By Product
Manual Tests
MIC Strips
Susceptibility Testing Disks
Susceptibility Plates
Automated Instruments
Consumables & Media
In 2023, the manual test segment accounted for a market share of 54.2%. As compared to automated tests, the large market share of this segment can be explained by ease of availability and low costs. In addition, the adoption of AST is increasing as a result of growing incidences of infectious diseases such as Shigella, Neisseria gonorrhoeae, Neisseria meningitides and others; are expected to drive the segment growth during the forecast period.
By Technique
Automated AST
Etest Method
Dilution
Disk Diffusion
Others
In 2023, the disk diffusion segment accounted for a revenue share of 42.3%. Various advantages such as ease of use and cost effectiveness can contribute to growth in the market. In addition, it provides for the possibility to carry out directly susceptibility tests in DST format which could shorten turnaround times. However, the American Society for Microbiology (ASM), the British Society for Antimicrobial Chemotherapy (BSAC), and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have voiced criticism towards DST, citing concerns about the lack of standardization in the inoculum employed for such tests.
By Application
Drug Development
Susceptibility Testing
Others
In 2023, the segment of susceptibility testing accounted for the largest revenue share of 39.5%. This market share is due to the high incidence of infectious diseases, increasing drug resistance and growing acceptance of AST as a treatment regimen for individual patients. Furthermore, market growth is supported by growing government initiatives aimed at raising awareness of antimicrobial testing. The adoption of ASTs for the detection of microbes and for the selection of effective treatments is also increasing due to the increasing incidence of healthcare associated infections.
By End-Use
Hospitals
Diagnostic Laboratories
Biotechnology & Pharmaceutical Companies
Others
Hospitals accounted for a 38.9% market share in 2023 due to increasing hospital infections and increasing cases of multidrug resistant infectious diseases, due to antibiotic misuse and lack of awareness about the use of antibiotics in developing countries are major drivers for market growth. To identify suspected infections, susceptibility tests are also carried out for different antimicrobials. In this case, the AST test is extremely efficient in detection of resistivity and sensitivity to microbes so that it can be selected as an optimum regimen.
Need any customization research on Antimicrobial Susceptibility Testing Market - Enquiry Now
In 2023, North America commanded the overall market with a revenue share of 46.8% and is expected to retain its dominance over the forecast period. Regional market growth is expected to be driven by rising incidences of infectious diseases, increasing antimicrobial resistance, and an increasing number of research activities related to the introduction of novel treatments for infections in the region.
Asia Pacific is expected to grow at a faster rate than any other region over the forecast period. The key drivers of growth in this region are the increasing number of R&D activities on new therapeutic products for infections, improved healthcare sector and government initiatives aimed at reducing illness burden. In addition, the demand for antibacterial susceptibility testing in this region is expected to increase as more and more people adopt tailored treatment options with regard to infectious diseases.
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Some of the major key players are as follows: Bio-Rad, BD, Danaher, Thermo Fisher Scientific, Accelerate Diagnostics, Merck Group, Creative Diagnostics, Alifax, Roche Diagnostics Limited, Synbiosis and Other Players.
In January 2023, bioMerieux has introduced MAESTRIA, an innovative AI tool. Their commitment to the development of automation in diagnostics is reflected in this addition to their product portfolio.
In May 2022, Qualigen Therapeutics made an announcement regarding its strategic partnership with NanoSynex Ltd. Qualigen recently completed agreements to acquire a controlling interest in NanoSynex, a company that demonstrated its advanced technology at BioMed Israel. NanoSynex's revolutionary technology is designed to significantly speed up the results of antimicrobial susceptibility tests and in doing so, reduce the time needed by a remarkable six times.
In April 2022, in particular in the area of identification and antimicrobial susceptibility testing, COPAN Diagnostics has taken the opportunity to demonstrate its full range of fully automated solutions for clinical microbiology. This demonstration took place at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID2022). The presentation of the FDA cleared Colibri, a complete automated specimen preparation device, was one notable event. For the preparation of MALDITOF identification targets and for the production of bacterial suspensions for AST, it is specifically designed.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 3.57 Billion |
| Market Size by 2031 | US$ 5.66 Billion |
| CAGR | CAGR of 5.9% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Manual Tests, Automated Instruments, Consumables & Media) • By Technique (Automated AST, Etest Method, Dilution, Disk Diffusion, Others) • By Application (Drug Development, Susceptibility Testing, Others) • By End-use (Hospitals, Diagnostic Laboratories, Biotechnology & Pharmaceutical Companies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Bio-Rad, BD, Danaher, Thermo Fisher Scientific, Accelerate Diagnostics, Merck Group, Creative Diagnostics, Alifax, Roche Diagnostics Limited, and Synbiosis. |
| DRIVERS | • Advancements in technology • Government efforts to detect and control antimicrobial-resistant species are becoming more widespread. • Drug misuse leads to the development of multidrug resistance. |
| RESTRAINTS | • Automated ID/AST systems are extremely expensive. |
Ans: The expected CAGR of the global Antimicrobial Susceptibility Testing Market during the forecast period is 5.2%.
Ans: The Antimicrobial Susceptibility Testing Market was valued at USD 3.57 billion in 2023.
Antimicrobial Susceptibility Testing Market is divided into four segments and they are By Product, By Type, By Method, and By End User.
North America now holds the bulk of the worldwide antimicrobial susceptibility testing market share, and is expected to do so for the foreseeable future.
The antimicrobial susceptibility testing segment dominated the market.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Antimicrobial Susceptibility Testing Market, by Product
9.1 Introduction
9.2 Trend Analysis
9.3 Manual Tests
9.3.1 MIC Strips
9.3.1 Susceptibility Testing Disks
9.3.1 Susceptibility Plates
9.4 Automated Instruments
9.5 Consumables & Media
10. Antimicrobial Susceptibility Testing Market, by Technique
10.1Introduction
10.3 Trend Analysis
10.4 Automated AST
10.5 Etest Method
10.6 Dilution
10.7 Disk Diffusion
10.8 Others
11. Antimicrobial Susceptibility Testing Market, by Application
11.1 Introduction
11.3 Trend Analysis
11.4 Drug Development
11.5 Susceptibility Testing
11.6 Others
12. Antimicrobial Susceptibility Testing Market, by End-use
12.1 Introduction
12.2 Trend Analysis
12.3 Hospitals
12.4 Diagnostic Laboratories
12.5 Biotechnology & Pharmaceutical Companies
12.6 Others
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 USA
13.2.2 Canada
13.2.3 Mexico
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Poland
13.3.1.2 Romania
13.3.1.3 Hungary
13.3.1.4 Turkey
13.3.1.5 Rest of Eastern Europe
13.3.2 Western Europe
13.3.2.1 Germany
13.3.2.2 France
13.3.2.3 UK
13.3.2.4 Italy
13.3.2.5 Spain
13.3.2.6 Netherlands
13.3.2.7 Switzerland
13.3.2.8 Austria
13.3.2.9 Rest of Western Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 India
13.4.3 Japan
13.4.4 South Korea
13.4.5 Vietnam
13.4.6 Singapore
13.4.7 Australia
13.4.8 Rest of Asia Pacific
13.5 The Middle East & Africa
13.5.1 Middle East
13.5.1.1 UAE
13.5.1.2 Egypt
13.5.1.3 Saudi Arabia
13.5.1.4 Qatar
13.5.1.5 Rest of the Middle East
13.5.2 Africa
13.5.2.1 Nigeria
13.5.2.2 South Africa
13.5.2.3 Rest of Africa
13.6 Latin America
13.6.1 Brazil
12.6.2 Argentina
13.6.3 Colombia
13.6.4 Rest of Latin America
14. Company Profiles
14.1 Bio-Rad
14.1.1 Company Overview
14.1.2 Financial
14.1.3 Products/ Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 BD
14.2.1 Company Overview
14.2.2 Financial
14.2.3 Products/ Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Danaher
14.3.1 Company Overview
14.3.2 Financial
14.3.3 Products/ Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Thermo Fisher Scientific
14.4.1 Company Overview
14.4.2 Financial
14.4.3 Products/ Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 Accelerate Diagnostics
14.5.1 Company Overview
14.5.2 Financial
14.5.3 Products/ Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 Merck Group
14.6.1 Company Overview
14.6.2 Financial
14.6.3 Products/ Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 Creative Diagnostics
14.7.1 Company Overview
14.7.2 Financial
14.7.3 Products/ Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Alifax
14.8.1 Company Overview
14.8.2 Financial
14.8.3 Products/ Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 Roche Diagnostics Limited
14.9.1 Company Overview
14.9.2 Financial
14.9.3 Products/ Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Synbiosis
14.10.1 Company Overview
14.10.2 Financial
14.10.3 Products/ Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. Use Case and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Clinical Workflow Solutions Market Size was valued at USD 11.07 billion in 2023 and will reach $32.71 billion by 2032, growing at a CAGR of 12.81% over the forecast period of 2024-2032.
The Laboratory Freezers Market was valued at USD 4.97 Billion in 2023 and is projected to reach USD 7.88 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.31% from 2024 to 2032.
The Cardiovascular Devices Market size was estimated at USD 51.97 billion in 2023 and is expected to reach USD 97.16 billion by 2032 at a CAGR of 7.2% during the forecast period of 2024-2032.
The Global Biosimilars Market Size was USD 29.51 Billion in 2023 and expected to reach USD 127.92 Billion By 2032 and grow at a CAGR of 17.7% by 2024-2032.
The Biochips Market was valued at USD 10.35 billion in 2023 and is expected to reach USD 35.00 billion by 2032, growing at a CAGR of 14.52% from 2024 to 2032.
The Cell Therapy Market was valued at USD 4.65 Billion in 2023 and is expected to reach USD 28.98 billion by 2032 and grow at a CAGR of 22.55% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
